Literature DB >> 35854091

Antibiotic exposures and the development of pediatric autoimmune diseases: a register-based case-control study.

Heli T Viljakainen1,2, Kaija-Leena Kolho3,4,5, Laura K Räisänen6,1,7, Sohvi E Kääriäinen8, Reijo Sund9, Elina Engberg1,2.   

Abstract

BACKGROUND: Antibiotics have been associated with several individual autoimmune diseases (ADs). This study aims to discover whether pre-diagnostic antibiotics are associated with the onset of ADs in general.
METHODS: From a cohort of 11,407 children, 242 developed ADs (type 1 diabetes, autoimmune thyroiditis, juvenile idiopathic arthritis (JIA), or inflammatory bowel diseases) by a median age of 16 years. Antibiotic purchases from birth until the date of diagnosis (or respective date in the matched controls n = 708) were traced from national registers.
RESULTS: Total number of antibiotic purchases was not related to the onset of ADs when studied as a group. Of specific diagnoses, JIA was associated with the total number of antibiotics throughout the childhood and with broad-spectrum antibiotics before the age of 3 years. Intriguingly, recent and frequent antibiotic use (within 2 years before diagnosis and ≥3 purchases) was associated with the onset of ADs (OR 1.72, 95% CI 1.08-2.74). Regardless of frequent use in childhood (40% of all antibiotics), penicillin group antibiotics were not related to any ADs.
CONCLUSIONS: Use of antibiotics was relatively safe regarding the overall development of ADs. However, broad-spectrum antibiotics should be used considerately as they may associate with an increased likelihood of JIA. IMPACT: Increasing numbers of antibiotic purchases before the age of 3 years or throughout childhood were not associated with the development of pediatric autoimmune diseases. Broad-spectrum antibiotics were related to the development of autoimmune diseases, especially juvenile idiopathic arthritis in children, while penicillin group antibiotics were not. The use of broad-spectrum antibiotics in children should be cautious as they may carry along a risk for autoimmune disease development.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 35854091     DOI: 10.1038/s41390-022-02188-4

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.953


  46 in total

Review 1.  Intestinal antigen-presenting cells in mucosal immune homeostasis: crosstalk between dendritic cells, macrophages and B-cells.

Authors:  Elizabeth R Mann; Xuhang Li
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 2.  Old and New Lymphocyte Players in Inflammatory Bowel Disease.

Authors:  Paolo Giuffrida; Gino Roberto Corazza; Antonio Di Sabatino
Journal:  Dig Dis Sci       Date:  2017-12-23       Impact factor: 3.199

Review 3.  Autoimmune thyroid disorders.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Alda Corrado; Andrea Di Domenicantonio; Poupak Fallahi
Journal:  Autoimmun Rev       Date:  2014-10-25       Impact factor: 9.754

Review 4.  New IBD genetics: common pathways with other diseases.

Authors:  C W Lees; J C Barrett; M Parkes; J Satsangi
Journal:  Gut       Date:  2011-02-07       Impact factor: 23.059

Review 5.  Autoantibodies in type 1 diabetes.

Authors:  Craig E Taplin; Jennifer M Barker
Journal:  Autoimmunity       Date:  2008-02       Impact factor: 2.815

Review 6.  Autoreactive T cells in type 1 diabetes.

Authors:  Alberto Pugliese
Journal:  J Clin Invest       Date:  2017-08-01       Impact factor: 14.808

7.  Emerging patterns of genetic overlap across autoimmune disorders.

Authors:  Corinne Richard-Miceli; Lindsey A Criswell
Journal:  Genome Med       Date:  2012-01-27       Impact factor: 11.117

Review 8.  Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases.

Authors:  Eleonore Fröhlich; Richard Wahl
Journal:  Front Immunol       Date:  2017-05-09       Impact factor: 7.561

Review 9.  On type 1 diabetes mellitus pathogenesis.

Authors:  Stavroula A Paschou; Nektaria Papadopoulou-Marketou; George P Chrousos; Christina Kanaka-Gantenbein
Journal:  Endocr Connect       Date:  2017-11-30       Impact factor: 3.335

Review 10.  Mucus barrier, mucins and gut microbiota: the expected slimy partners?

Authors:  Paola Paone; Patrice D Cani
Journal:  Gut       Date:  2020-09-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.